TITLE

Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease

AUTHOR(S)
Sin, Don D.; Tu, Jack V.
PUB. DATE
March 2000
SOURCE
Thorax;Mar2000, p194
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877278

 

Related Articles

  • Ipratropium bromide.  // Reactions Weekly;Jun2014, Vol. 1507 Issue 1, p20 

    An abstract of the article "Stress-induced cardiomyopathy associated with ipratropium bromide therapy in a patient with chronic obstructive pulmonary disease," by F. Melao and colleagues is presented.

  • ACP Journal Club. Review: In COPD, tiotropium improves lung function and reduces adverse events compared with ipratropium bromide. Maselli, Diego J.; Peters, Jay I. // Annals of Internal Medicine;1/19/2016, Vol. 164 Issue 2, pJC6 

    The article reports on a study regarding the comparison of efficacy of tiotropium and ipratropium bromide in patients with chronic obstructive pulmonary disease (COPD) that reveals that tiotropium increases FEV1 and improves lung disease in comparison to ipratropium bromide. Topics discussed...

  • Ipratropium and CV events in COPD. Kuritzky, Louis // Clinical Oncology Alert;Apr2010 Supplement 2, p7 

    The article discusses research on the link between ipratropium bromide and cardiovascular events in patients with chronic obstructive pulmonary disease (COPD), by S. S. Ogale and colleagues, published in the 2010 issue of "Chest."

  • ipratropium bromide.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1230 

    A definition of the term "ipratropium bromide" which refers to an anticholinergic bronchodilator used for bronchoconstriction associated with chronic bronchitis, chronic obstructive pulmonary disease, emphysema, and asthma is presented.

  • Tiotropium bromide improves outcomes, QOL at acceptable cost.  // PharmacoEconomics & Outcomes News;2/28/2004, Issue 447, p7 

    Provides information on a study regarding the improved health outcomes and quality of life in patients with chronic obstructive pulmonary disease who were treated with tiotropium bromide. Comparison between the exacerbations of patients who received tiotropium bromide and patients who received...

  • Ipratropium bromide is more effective than Salmeterol - Fluticason combination on O2 saturation patients with COPD. Rezaie, Nader; Sadat Shams-Hosseini, Narges; Kashanizadeh, Atefeh; Karimi, Mohammad Ali // Journal of Research in Medical Sciences;Aug2013, Vol. 18 Issue 8, p731 

    A letter to the editor is presented on a study investigating the effectiveness of Ipratropium bromide and Salmeterol Fluticason (SFC) in chronic obstructive pulmonary disease (COPD) patients.

  • Ipratropium associated with increased risk of death in patients with COPD.  // Formulary;Oct2008, Vol. 43 Issue 10, p381 

    The article discusses the case-control analysis on the association of ipratropium with the mortality rate of chronic obstructive pulmonary disease (COPD) patients. According to the author, the study uses information from Veterans Affairs databases and Centers for Medicare & Medicaid Services. As...

  • Acute angle closure glaucoma occurring after nebulized bronchodilator treatment with ipratropium bromide and salbutamol. Reuser, T.; Flanagan, D. W.; Borland, C.; Bannerjee, D. K. // Journal of the Royal Society of Medicine;Aug1992, Vol. 85 Issue 8, p499 

    The article presents two case reports related to the occurrence of an acute angle closure after nebulized bronchodilator treatment with ipratropium bromide and salbutamol. A 64-year-old woman, with longstanding chronic obstructive airways disease who developed severe dyspnoea secondary basal...

  • Modelling the cost effectiveness of bronchodilators in COPD.  // PharmacoEconomics & Outcomes News;2/12/2005, Issue 471, p10 

    Discusses research being done on the cost effectiveness of bronchodilators in patients with chronic obstructive pulmonary disease (COPD). Reference to a study by J. M. Oostenbrink and colleagues, published in the January 2005 issue of the "Value in Health"; Model used in the assessment of costs...

  • Role of tiotropium in chronic obstructive pulmonary disease exacerbation. Pant, P.; Yadav, B.; Khan, G. M.; Koju, R.; Gurung, R.; Pokharel, B.; Bedi, T. R. S.; Adkhari, R. K. // Journal of Institute of Medicine;Aug2010, Vol. 32 Issue 2, p5 

    Introduction: Chronic obstructive pulmonary disease (COPD) remains a major public health problem. Many patients suffering from chronic obstructive lungs diseases are of poor economic status, mostly illiterate, therefore has a direct bearing on patient compliance. Tiotropium is a new...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics